PF-Atlas › Clinical Trials › NCT00095732

Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

Liprotamase · Phase 2

Registry ID
NCT00095732
Phase
Phase 2
Status
Completed
Drug / intervention
Liprotamase
Sponsor
Anthera Pharmaceuticals
Start
2004-06
Enrollment
129
Locations
27

About this trial

The purpose of this study is to determine the most effective dose of a new enzyme therapy on oral nutrient absorption in cystic fibrosis (CF) subjects with exocrine pancreatic insufficiency.

View NCT00095732 on ClinicalTrials.gov →

Explore related

All Liprotamase trialsAll IPF trials

Related trials

Liprotamase — NCT00449904Liprotamase — NCT02823964
Medical disclaimer. This page summarizes public trial data for NCT00095732 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.